{"id":"https://openalex.org/W2014842777","doi":"https://doi.org/10.1517/14712598.2010.522904","title":"Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules","display_name":"Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules","publication_year":2010,"publication_date":"2010-10-19","ids":{"openalex":"https://openalex.org/W2014842777","doi":"https://doi.org/10.1517/14712598.2010.522904","mag":"2014842777","pmid":"https://pubmed.ncbi.nlm.nih.gov/20955110"},"language":"en","primary_location":{"id":"doi:10.1517/14712598.2010.522904","doi":"https://doi.org/10.1517/14712598.2010.522904","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14712598.2010.522904","pdf_url":null,"source":{"id":"https://openalex.org/S57380513","display_name":"Expert Opinion on Biological Therapy","issn_l":"1471-2598","issn":["1471-2598","1744-7682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Biological Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041033274","display_name":"Sumanta Kumar Pal","orcid":"https://orcid.org/0000-0002-1712-0848","observed_orcids":["https://orcid.org/0000-0002-1712-0848"]},"institutions":[{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumanta Kumar Pal","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center, Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, Los Angeles, CA, USA +1 626 256 4673; +1 626 301 8233; spal@coh.org","+1 626 301 8233","City of Hope Comprehensive Cancer Center, Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, Los Angeles, CA, USA +1 626 256 4673"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, Los Angeles, CA, USA +1 626 256 4673; +1 626 301 8233; spal@coh.org","institution_ids":["https://openalex.org/I4210110459"]},{"raw_affiliation_string":"+1 626 301 8233","institution_ids":[]},{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, Los Angeles, CA, USA +1 626 256 4673","institution_ids":["https://openalex.org/I4210110459"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050649350","display_name":"Robert A. Figlin","orcid":"https://orcid.org/0000-0002-6323-6075","observed_orcids":["https://orcid.org/0000-0002-6323-6075"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A Figlin","raw_affiliation_strings":["Hematology-Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology-Oncology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I1282927834"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5316,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.72859677,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"10","issue":"11","first_page":"1517","last_page":"1520"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.8230000138282776},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9089999794960022},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8240000009536743},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9269999861717224},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6850000023841858},{"id":"https://openalex.org/keywords/clinical-equipoise","display_name":"clinical equipoise","score":0.7310000061988831},{"id":"https://openalex.org/keywords/biomarker-analysis","display_name":"biomarker analysis","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8302223682403564},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.7600867748260498},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7025936245918274},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6098058223724365},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5762755870819092},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5133361220359802},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.4974205791950226},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.48690807819366455},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.457955002784729},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32035040855407715},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.20028167963027954},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17643660306930542},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077210","descriptor_name":"Sunitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14712598.2010.522904","doi":"https://doi.org/10.1517/14712598.2010.522904","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14712598.2010.522904","pdf_url":null,"source":{"id":"https://openalex.org/S57380513","display_name":"Expert Opinion on Biological Therapy","issn_l":"1471-2598","issn":["1471-2598","1744-7682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Biological Therapy","raw_type":"journal-article"},{"id":"pmid:20955110","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20955110","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on biological therapy","raw_type":"Editorial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/14","score":0.8399999737739563,"display_name":"Life below water"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5053255470","display_name":null,"funder_award_id":"K12 2K12CA001727-16A1","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G6104376904","display_name":"City of Hope Clinical Oncology Career Research Development Program","funder_award_id":"K12CA001727","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320314458","display_name":"National Comprehensive Cancer Network","ror":"https://ror.org/0465x5x63"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1748790266","https://openalex.org/W2030869361","https://openalex.org/W2046507292","https://openalex.org/W2099752220","https://openalex.org/W2104540972","https://openalex.org/W2110320497","https://openalex.org/W2115005218","https://openalex.org/W2125651014","https://openalex.org/W2126275851","https://openalex.org/W2127159621","https://openalex.org/W2127745545","https://openalex.org/W2131705241","https://openalex.org/W2145835533","https://openalex.org/W2153867442","https://openalex.org/W2155012968","https://openalex.org/W2157769714","https://openalex.org/W2160476851","https://openalex.org/W2162424705","https://openalex.org/W2248877739","https://openalex.org/W2279064713","https://openalex.org/W2514075555","https://openalex.org/W2590187012"],"related_works":["https://openalex.org/W2119565846","https://openalex.org/W2160476851","https://openalex.org/W2135258573","https://openalex.org/W1967961191","https://openalex.org/W1970779535","https://openalex.org/W2129608087","https://openalex.org/W3009736595","https://openalex.org/W2073582873","https://openalex.org/W2155012968","https://openalex.org/W7095538499"],"abstract_inverted_index":{"Several":[0],"years":[1],"ago,":[2],"the":[3,15,24,39,55,81,118,126,146],"oncologist":[4],"was":[5],"limited":[6],"to":[7,95,139],"a":[8,29,51,101],"narrow":[9],"scope":[10],"of":[11,17,31,41,46,83,120,128,142,148],"immunotherapeutic":[12],"agents":[13,34],"for":[14,38,54],"treatment":[16,40,147],"metastatic":[18],"renal":[19],"cell":[20],"carcinoma":[21],"(mRCC).":[22],"Within":[23],"past":[25],"5":[26],"years,":[27],"however,":[28],"total":[30],"6":[32],"targeted":[33],"have":[35],"been":[36],"approved":[37],"this":[42],"disease.":[43],"The":[44],"abundance":[45],"novel":[47],"therapies":[48],"has":[49],"introduced":[50],"new":[52],"dilemma":[53],"oncologist--namely,":[56],"how":[57],"can":[58],"one":[59],"make":[60],"evidence-based":[61],"choices":[62],"amongst":[63],"available":[64],"agents?":[65],"Recently,":[66],"two":[67],"Phase":[68],"III":[69],"studies":[70],"(AVOREN":[71],"and":[72,74,154],"Cancer":[73],"Leukemia":[75],"Group":[76],"B":[77],"[CALGB]":[78],"90206)":[79],"assessed":[80,124],"activity":[82],"1st-line":[84],"therapy":[85],"with":[86,90,108,110],"bevacizumab":[87],"in":[88,104,113,125,136,145],"combination":[89],"interferon-alfa":[91],"(IFN-alfa)":[92],"as":[93],"compared":[94],"IFN-alfa":[96],"alone.":[97],"Both":[98],"trials":[99,135],"demonstrated":[100],"significant":[102],"benefit":[103,112],"progression-free":[105],"survival":[106,115],"(PFS)":[107],"bevacizumab,":[109],"no":[111],"overall":[114],"(OS).":[116],"Herein,":[117],"implications":[119],"these":[121],"data":[122,129],"are":[123,157],"context":[127],"reported":[130],"from":[131],"other":[132],"recent":[133],"pivotal":[134],"mRCC.":[137],"Methods":[138],"resolve":[140],"areas":[141],"clinical":[143],"equipoise":[144],"mRCC":[149],"(i.e.,":[150],"comparative":[151],"trial":[152],"designs":[153],"biomarker":[155],"analyses)":[156],"also":[158],"proposed.":[159]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}